Editorial
Iwona Rybakowska
Abstract
Recently D.H. Huller and D Baker from Department of Biochemistry University of Washington described the de novo protein design. Till now proteins were considered as therapeutics and at present they are being tested as targeted therapeutics. Early work of Paul Ehrlich provided small molecule drugs for the treatment of infectious diseases, metabolic disorders, cardiac diseases, neuromedicine and cancer. Among these were protein drugs like antibodies. More than 20 different antibodies have been approved in Europe and USA [1] as potential pharmaceuticals for pharmaceutical industry.